M/21/074 – Pelican Bidco/Cruinn Diagnostics
The proposed acquisition of sole control by Pelican Bidco Limited of Cruinn Diagnostics Limited has been cleared by the Competition and Consumer Protection Commission.
|Notification date||Decision date|
|Tuesday December 14, 2021||Thursday, December 30, 2021|
|Parties Involved||Business activities|
|Pelican Bidco Limited||
Pelican Bidco Limited is a private limited company incorporated in Ireland, and established for the purposes of the Proposed Transaction. It is controlled by funds managed by MML Growth Capital Partners Ireland II Limited. These funds are private equity funds, providing growth capital to private businesses on the island of Ireland for expansion, acquisitions, recapitalisations and shareholder reorganisations.
|Cruinn Diagnostics Limited||
Cruinn is a distributor and supplier of laboratory diagnostic instruments and consumables to customers in the medical, pharmaceutical, independent laboratory and university spaces. Cruinn also undertakes associated services such as maintenance, calibration and some limited laboratory testing. Cruinn is active in the biochemistry, microbiology, haematology and histopathology segments of the market. Cruinn operates from its base in Dublin.
|Economic sector||Media merger|
|Submissions from third parties due by:|
|Phase 1||Phase 2|
|Wednesday, December 29, 2021|
|Current status: Completed|
|Cleared (Phase 1)|
|Authorised Officer Assigned||Contact Details|
Media enquiries: email@example.com